Loading...
NPI 1144757212 · New Castle, DE · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Delaware Diagnostic Labs, LLC is a clinical medical laboratory provider located in New Castle, Delaware. This profile covers 85 Medicare and 55 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Delaware Diagnostic Labs, LLC |
| Address | 900 Uniqema Blvd |
| City | New Castle |
| State | DE |
| ZIP | 19720 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | May 19, 2017 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $8.5M |
| Medicare | $3.1M |
DELAWARE DIAGNOSTIC LABS, LLC reports materially more Medicaid activity than Medicare, with total Medicaid revenue of $8.5M versus total Medicare revenue of $3.1M; this provider therefore operates with a Medicaid-dominant revenue base rather than being Medicare-led. The disparity in scale suggests that state-level contracts or high-volume Medicaid testing programs are the primary commercial drivers for the lab.
Revenue concentration is high on both payers: precomputed data show the top 3 Medicare codes by revenue account for 59.8% of Medicare revenue, while the top 3 Medicaid codes by revenue account for 80.5% of Medicaid revenue. On Medicare the single largest code is G0483 ($809.5K, 26.7% of Medicare revenue), and on Medicaid the single largest code is U0004 ($4.1M, 48.7% of Medicaid revenue), indicating reliance on a small number of high-yield services.
The provider’s Medicare portfolio is concentrated in definitive drug testing and SARS-CoV-2 molecular testing: G0483 ($809.5K, 26.7% Medicare) is the top Medicare revenue code and 87636 ($409.6K, 13.5% Medicare) and U0004 ($589.6K, 19.5% Medicare) complete the highest-revenue mix. This code mix implies the lab operates high-complexity chemistry and molecular platforms capable of GC/MS or LC/MS definitive drug panels and high-throughput nucleic acid testing, positioning it as a specialized diagnostic lab rather than a routine hospital lab.
Medicaid billing is overwhelmingly driven by high-throughput COVID-19 testing and definitive drug panels: U0004 ($4.1M, 48.7% Medicaid) and G0481 ($2.3M, 27.4% Medicaid) together account for the majority of Medicaid revenue, with U0005 ($372.5K, 4.4% Medicaid) also among the top three. The dominance of U0004 and G0481 in the Medicaid mix indicates the lab’s business was heavily oriented toward mass SARS-CoV-2 testing and expansive drug-testing services during the reporting period.
Specimen collection and high-volume throughput are evident across payers: G2023 shows 8.7K Medicare claims ($199.9K, 6.6% Medicare) and 59.6K Medicaid claims ($357.6K, 4.2% Medicaid), reflecting a substantial specimen-collection footprint. The prevalence of collection codes alongside high counts for U0004 and U0005 signals an operational model that includes wide specimen intake and rapid processing capacity.
National competitive standing for key Medicare codes is strong for several SARS-CoV-2 and molecular test codes: 87636 ranks #13 of 2192 providers nationally (99th percentile; noted as notably above typical national volume) and U0004 ranks #9 of 259 (97th percentile; notably above typical national volume). Conversely, G0483 ranks #26 of 1063 (98th percentile) but is described in the data as typical, unremarkable volume for this code, indicating strong placement on national leaderboards for molecular testing while drug-testing volumes may reflect common patterns among specialized labs.
At the state level the lab is a dominant Medicaid supplier for multiple codes: U0004 ranks #1 of 8 in-state (100th percentile; notably above typical state volume), G2023 ranks #1 of 15 (100th percentile; extreme outlier, far above typical state volume), and U0005 ranks #1 of 7 (100th percentile; notably above typical state volume). Multiple #1 in-state rankings show the provider is a major Medicaid testing resource in Delaware for COVID-19 and related molecular services.
The provider’s NPI was enumerated on 2017-05-19 (~9 years ago), indicating it has several years of operational tenure; coupled with the mix of high-complexity testing codes and high claim counts, this suggests an established outpatient laboratory operation with mature service lines in molecular diagnostics and definitive toxicology.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
85 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3,350 | $240 | $809.5K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 7,970 | $70 | $589.6K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 2,930 | $140 | $409.6K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 8,690 | $20 | $199.9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 7,940 | $30 | $198.4K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 5,460 | $30 | $185.6K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 3,700 | $50 | $185.2K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 820 | $140 | $114.1K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 410 | $200 | $79.2K |
| 87186 | The lab analyst performs the technical steps to evaluate a culture isolate’s susceptibility, or sensitivity, to multiple antimicrobial agents, commonly called antibiotics, by observing growth of the… | 3,490 | $10 | $27.9K |
Showing 1–10 of 85
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 85 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
55 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 85,860 | $50 | $4.1M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 19,360 | $120 | $2.3M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 53,210 | $10 | $372.5K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 59,600 | $10 | $357.6K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 3,110 | $100 | $317K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 3,440 | $80 | $288.6K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 2,300 | $80 | $176.9K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 3,910 | $40 | $160.3K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3,390 | $30 | $101.7K |
| 87186 | The lab analyst performs the technical steps to evaluate a culture isolate’s susceptibility, or sensitivity, to multiple antimicrobial agents, commonly called antibiotics, by observing growth of the… | 2,610 | $20 | $52.3K |
Showing 1–10 of 55
How this provider's Medicaid billing volume and revenue compare to other Delaware providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Delaware median
55 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 2 | 10 | 2,300 | $180 | $1.2M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 1 | 10 | 3,340 | $50 | $710.4K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 10 | 1,330 | $70 | $462.8K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 10 | 10 | 19,870 | $20 | $426.3K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 6 | 10 | 1,960 | $30 | $294.9K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 11 | 20 | 3,450 | $30 | $287.8K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 5 | 10 | 430 | $270 | $247.1K |
| 80048 | The lab analyst performs a basic metabolic pane (BMP) test in which he measures the blood level of eight chemicals including total calcium, sodium, potassium, chloride, carbon dioxide, glucose, blood… | 11 | 10 | 7,360 | $10 | $214.1K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 13 | 20 | 5,800 | $30 | $198.6K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 2 | 10 | 490 | $100 | $183.2K |
Showing 1–10 of 55
Other providers in the same ZIP code as Delaware Diagnostic Labs, LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.